Head-to-head · free
Nabtesco Corporation vs Acumen Pharmaceuticals
6268.T vs ABOS — return on capital, cash generation, margins and balance sheet side by side.
6268.T
1 / 1
measures where 6268.T leads
ABOS
0 / 1
measures where ABOS leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | 6268.T · FY2025 | ABOS · FY2025 |
|---|---|---|
| Revenue | $307.9B | — |
| Net income | $15.7B | (121.3M) |
| Revenue growth (yearly, multi-year) | -4.8% | — |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | -96.2% |
| Gross margin | — | — |
| Operating margin | — | — |
| Net debt / EBITDA | — | 0.18x |
Figures are as reported by each company; latest fiscal year shown.
Where Nabtesco Corporation's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Acumen Pharmaceuticals's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free